Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

LiangMin Fu

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Regenerative Biomaterials|April 20, 2023
Quercetin-solid lipid nanoparticle-embedded hyaluronic acid functionalized hydrogel for immunomodulation to promote bone reconstructionPinghui Zhou, Bomin Yan, Bangguo Wei, et al.
Cell Death & Disease|February 23, 2025
STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosisYihui Pan, Shuang Liu, Guannan Shu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 24, 2026
Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell CarcinomaXingyue Yang, Baoshuai Liang, Liangmin Fu, et al.
Journal of Inflammation Research|April 3, 2023
Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-CancerXinwei Zhou, Ke Lin, Liangmin Fu, et al.
Translational Andrology and Urology|April 10, 2023
Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinomaMinyu Chen, Pengju Li, Haohua Yao, et al.
Cell Death and Differentiation|December 13, 2024
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axisAnze Yu, Liangmin Fu, Lanyu Jing, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8<sup>+</sup> T cell infiltration and functional transitionAnze Yu, Jiao Hu, Liangmin Fu, et al.
Cancer Medicine|March 1, 2022
The impact of tumor size on the survival of patients with small renal masses: A population-based studyYiming Tang, Fei Liu, Xiaopeng Mao, et al.
Cell Proliferation|May 16, 2025
Deciphering the Immunomodulatory Function of GSN<sup>+</sup> Inflammatory Cancer-Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan-Cancer Single-Cell Landscape and Spatial Transcriptomics AnalysisShan Li, Xinwei Zhou, Haoqian Feng, et al.
Frontiers in Immunology|August 8, 2025
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapyWuyuan Liao, Xinwei Zhou, Hansen Lin, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Regenerative Biomaterials|April 20, 2023
Quercetin-solid lipid nanoparticle-embedded hyaluronic acid functionalized hydrogel for immunomodulation to promote bone reconstructionPinghui Zhou, Bomin Yan, Bangguo Wei, et al.
Cell Death & Disease|February 23, 2025
STX17-DT facilitates axitinib resistance in renal cell carcinoma by inhibiting mitochondrial ROS accumulation and ferroptosisYihui Pan, Shuang Liu, Guannan Shu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 24, 2026
Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell CarcinomaXingyue Yang, Baoshuai Liang, Liangmin Fu, et al.
Journal of Inflammation Research|April 3, 2023
Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-CancerXinwei Zhou, Ke Lin, Liangmin Fu, et al.
Translational Andrology and Urology|April 10, 2023
Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinomaMinyu Chen, Pengju Li, Haohua Yao, et al.
Cell Death and Differentiation|December 13, 2024
Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axisAnze Yu, Liangmin Fu, Lanyu Jing, et al.
Journal for Immunotherapy of Cancer|October 6, 2023
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8<sup>+</sup> T cell infiltration and functional transitionAnze Yu, Jiao Hu, Liangmin Fu, et al.
Cancer Medicine|March 1, 2022
The impact of tumor size on the survival of patients with small renal masses: A population-based studyYiming Tang, Fei Liu, Xiaopeng Mao, et al.
Cell Proliferation|May 16, 2025
Deciphering the Immunomodulatory Function of GSN<sup>+</sup> Inflammatory Cancer-Associated Fibroblasts in Renal Cell Carcinoma Immunotherapy: Insights From Pan-Cancer Single-Cell Landscape and Spatial Transcriptomics AnalysisShan Li, Xinwei Zhou, Haoqian Feng, et al.
Frontiers in Immunology|August 8, 2025
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapyWuyuan Liao, Xinwei Zhou, Hansen Lin, et al.
Pageof 3